Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04819789
Other study ID # NL74595.081.20
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 13, 2021
Est. completion date May 20, 2021

Study information

Verified date May 2021
Source Wageningen University and Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to assess the degree of digestibility of 3 different Fermotein™ products and compare this to a reference commercially available Mycoprotein (Quorn) and to assess the effects on blood glucose and insulin levels. The study has a randomized, cross-over, double blind, controlled design. Four different treatments, all representing a 20g protein load, will be evaluated with a washout period of minimum one week between the test days. On test days, research subjects will receive a product e.g. Fermotein™ dry, Fermotein™ wet, modified Fermotein™ wet and a reference Mycoprotein (Quorn), in the form of a porridge, in randomized order. Blood will be collected via a catheter before and up-to five hours after protein consumption. Wellbeing, health complaints or other adverse effects will be collected via short questionnaires during each test day. After each test day gastrointestinal complaints are collected via an online questionnaire.


Description:

Mycoprotein is a protein source derived from fungi produced for human consumption. It is high in protein, high in fiber, low in saturated fat and contains no cholesterol. Their functional properties and nutrient content make them ideal to use as an ingredient for meat alternatives. Fermotein™ is such a mycoprotein type novel food source. The digestion characteristics of Fermotein™ are not known, but essential to evaluate their future potential as a sustainable protein source. Also, information on the degree of digestibility would strengthen a novel food dossier that is being constructed for this product. The primary objective is to assess the degree of digestibility of 3 different Fermotein™ products and compare this to a reference commercially available Mycoprotein (Quorn). Secondary objectives are to assess the effects on blood glucose and insulin levels. The study has a randomized, cross-over, double blind, controlled design. Four different treatments, all representing a 20g protein load, will be evaluated with a washout period of minimum one week between the test days. On test days, research subjects will receive a product e.g. Fermotein™ dry, Fermotein™ wet, modified Fermotein™ wet and a reference Mycoprotein (Quorn), in the form of a porridge, in randomized order. Blood will be collected via a catheter before and up-to five hours after protein consumption. Wellbeing, health complaints or other adverse effects will be collected via short questionnaires during each test day. After each test day gastrointestinal complaints are collected via an online questionnaire.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date May 20, 2021
Est. primary completion date May 20, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Apparently healthy men and women; - Age between 18 and 70 years; - Body mass index (BMI) between 18.5 and 30 kg/m2 ; - Having veins suitable for blood sampling via a catheter (judged by study nurse/ medical doctor). Exclusion Criteria: - Any metabolic, gastrointestinal, inflammatory or chronic disease (such as diabetes, anaemia, hepatitis, cardiovascular disease),or having a condition or disease that may lead to an impaired immune system - History of gastrointestinal surgery or having (serious) gastrointestinal complaints; - History of liver dysfunction (cirrhosis, hepatitis) or liver surgery; - Kidney dysfunction (self-reported); - Any use of medication that may suppress the immune system, this will be judged by the medical supervisor; - Use of medication that may influence the study results, such as gastric acid inhibitors, laxatives, stomach protectors and drugs that can affect intestinal motility, this will be judged by the medical supervisor; - Anaemia (Hb values <7.5 mmol/L for women and <8.5 mmol/L for men); - Reported slimming, medically prescribed or other extreme diets; - Not willing to give up blood donation during the study; - Current smokers; - Alcohol intake =4 glasses of alcoholic beverages per day; - Pregnant, lactating or wishing to become pregnant in the period of the study (self-reported); - Abuse of hard drugs; - Having food allergies; - Not having a general practitioner; - Participation in another clinical trial at the same time; - Being an employee of the department Food, Health & Consumer Research of Wageningen Food & Biobased Research.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Fermotein™ dry powder porridge
At one out of four test days: Fermotein™ dry powder mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
Fermotein™ wet porridge
At one out of four test days: Fermotein™ wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
Fermotein™ modified wet porridge
At one out of four test days: Fermotein™ modified wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
Mycoprotein porridge (matching control)
At one out of four test days: Mycoprotein (Quorn) mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.

Locations

Country Name City State
Netherlands Stichting Wageningen Research Wageningen Gelderland

Sponsors (2)

Lead Sponsor Collaborator
Wageningen University and Research The Protein Brewery

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in degree of digestibility In order to assess change in the degree of digestibility, we determine 19 free amino acids in blood samples collected via a catheter before and at several time points up-to five hours after protein source consumption. Blood amino acids will be determined by the laboratory of Wageningen FBR, according a valid method: AccQ-Tag ultra-derivation kit & HPLC. During the intervention period on 4 test days: at baseline and postprandial blood samples will be collected from the cannula at 10 time points (T=0, 30, 60, 75, 90, 120, 150, 180, 240, 300 minutes).
Secondary Change in plasma glucose levels Plasma glucose levels will be determined in blood samples collected via a catheter before and at several time points up-to five hours after protein source consumption (hospital laboratory Ziekenhuis Gelderse vallei, Ede, the Netherlands). During the intervention period on 4 test days: at baseline and postprandial blood samples will be collected from the cannula at 9 time points (T=0, 30, 60, 90, 120, 150, 180, 240, 300 minutes).
Secondary Change in plasma insulin levels Plasma insulin levels will be determined in blood samples collected via a catheter before and at several time points up-to five hours after protein source consumption (hospital laboratory Ziekenhuis Gelderse vallei, Ede, the Netherlands). During the intervention period on 4 test days: at baseline and postprandial blood samples will be collected from the cannula at 9 time points (T=0, 30, 60, 90, 120, 150, 180, 240, 300 minutes).
See also
  Status Clinical Trial Phase
Completed NCT00671177 - Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique N/A
Completed NCT05118412 - Personal Protein Digestion Variability N/A
Completed NCT05426122 - Degree of Digestibility of Barley Rice Proteins N/A
Not yet recruiting NCT06396728 - Use of GI BIOTICS 100B UFC to Improve Intestinal Health in Older Adults N/A